Abstract: Method and kits for detecting cancer, and in particular breast cancer, in a subject by measuring the levels of at least one of a series of biomarkers, as compared to a control sample lacking cancer. The expression of the biomarker either increases or decreases in samples from subjects with cancer, as compared to the expression level in subjects without cancer. The sample is optimally an ocular sample, such as an isolated tear sample or ocular wash, but can also be from saliva, or other bodily fluid. Kits can include a collection tube and protease inhibitors or protein stabilizers.

Abstract: Provided are methods, compositions, kits and the like, for diagnosing and differentiating patients with systemic juvenile idiopathic arthritis (sJIA) from patients with Kawasaki disease (KD) and other febrile illnesses.

Abstract: The present disclosure is directed toward methods for obtaining and processing ocular fluid samples from a subject in preparation for further analysis for diagnostic purposes. Ocular fluid provides a superior sample medium for biomarker analysis as compared to other biological media such as blood, serum, saliva, urine or bodily secretions. Proper sample collection and processing is critical for further use as a diagnostic medium as studies have shown that biomarkers found in ocular fluid can degrade quickly if mishandled.

Abstract: The present disclosure is directed toward methods and kits for detecting cancer, and in particular breast cancer, in a subject by measuring the levels of at least one of the identified markers, as compared to a control. The expression of the markers in Table 2A is increased in samples from subjects with cancer as compared to the expression level in subjects without cancer and the expression of the markers in Table 2B are decreased in samples from subjects with cancer as compared to the expression level in subjects without cancer. The sample may be lacrimal secretions or eye wash fluid, saliva, or other biological fluids. The kits may include an eye wash kit, collection tubes and protease inhibitors, or protein stabilizers.

Abstract: Method and kits for detecting cancer, and in particular breast cancer, in a subject by measuring the levels of at least one of a series of biomarkers, as compared to a control sample lacking cancer. The expression of the biomarker either increases or decreases in samples from subjects with cancer, as compared to the expression level in subjects without cancer. The sample is optimally an ocular sample, such as an isolated tear sample or ocular wash, but can also be from saliva, or other bodily fluid. Kits can include a collection tube and protease inhibitors or protein stabilizers.

Abstract: Method and kits for detecting cancer, and in particular breast cancer, in a subject by measuring the levels of at least one of a series of biomarkers, as compared to a control sample lacking cancer. The expression of the biomarker either increases or decreases in samples from subjects with cancer, as compared to the expression level in subjects without cancer. The sample is optimally an ocular sample, such as an isolated tear sample or ocular wash, but can also be from saliva, or other bodily fluid. Kits can include a collection tube and protease inhibitors or protein stabilizers.

Abstract: The present disclosure is directed toward methods and kits for detecting cancer, and in particular breast cancer, in a subject by measuring the levels of at least one of the identified markers, as compared to a control. The expression of the markers in Table 2A is increased in samples from subjects with cancer as compared to the expression level in subjects without cancer and the expression of the markers in Table 2B are decreased in samples from subjects with cancer as compared to the expression level in subjects without cancer. The sample may be lacrimal secretions or eye wash fluid, saliva, or other biological fluids. The kits may include an eye wash kit, collection tubes and protease inhibitors, or protein stabilizers.